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Progressive neurodegeneration and decline 
of cognitive functions are major hallmarks 
of Alzheimer`s disease (AD*). 
Neurodegeneration in AD correlates with 
dysfunction of diverse signal transduction 
mechanisms such as the G-protein-
stimulated phosphoinositide hydrolysis 
mediated by Gαq/11. We report here that 
impaired Gαq/11-stimulated signaling in 
brain of AD patients and mice correlated 
with the appearance of cross-linked 
oligomeric angiotensin II AT2 receptors 
sequestering Gαq/11. Amyloid β (Aβ) was 
causal to AT2 oligomerization because 
cerebral microinjection of Aβ triggered AT2 
oligomerization in the hippocampus of mice 
in a dose-dependent manner. Aβ  induced 
AT2 oligomerization by a two-step process 
of oxidative and transglutaminase-
dependent cross-linking. The induction of 
AT2 oligomers in a transgenic mouse model 
with AD-like symptoms was associated with 
Gαq/11 dysfunction and enhanced 
neurodegeneration. Vice versa, stereotactic 
inhibition of AT2 oligomers by RNA 
interference prevented the impairment of 
Gαq/11, and delayed tau phosphorylation. 
Thus, Aβ induces the formation of cross-
linked AT2 oligomers that contribute to the 
dysfunction of Gαq/11 in an animal model of 
Alzheimer`s disease. 
 
Alzheimer`s disease (AD) is a protein 
aggregation disease that is characterized by 
profound neuropathological changes in brain 
including neurodegeneration, neurofibrillary 
tangles and the accumulation of fibrillar β 
amyloid (Aβ) in extracellular senile plaques. 
While some neuropathological features of AD 
such as tangles and plaques are also detected in 
brain of elderly people without major 
symptoms of dementia (1), neurodegeneration 
and neuronal loss of AD patients are associated 
with the major AD symptoms of memory 
impairment and dementia (2,3). 
Neurodegeneration in AD is accompanied by 
dysfunction of diverse signal transduction 
mechanisms such as the G-protein-stimulated 
phosphoinositide hydrolysis mediated by 
Gαq/11 (4-8). Gαq/11-stimulated signal 
transduction pathways are important for 
neuronal communication, synaptic plasticity 
and neuronal survival (9,10). Therefore it is 
likely that the Gαq/11 signaling defect of AD 
patients plays a role in the disease process 
leading to neurodegeneration and dementia. In 
agreement with this notion, G-protein 
dysfunction is directly associated with disease 
severity of AD patients (8). 
 Further insight into the pathological 
role of the G-protein dysfunction of AD 
patients is lacking, because the underlying 
mechanism is barely understood. Several 
observations point to a specific defect at the 
level of Gαq/11: (i) protein levels of Gαq/11 are 
not changed (7), (ii) downstream receptor/G-
protein-independent phosphoinositide 
hydrolysis is intact (7), and (iii) receptor-
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mediated activation of other G-proteins such as 
the Gαi/o proteins is not affected (5). In view of 
a putative role in the pathogenesis, we 
investigated the mechanism accounting for 
defective Gαq/11 activation in AD. 
 Gαq/11 activation is under control of 
specific receptors. While most receptors 
interacting with Gαq/11 stimulate guanine 
nucleotide exchange and thereby trigger 
Gαq/11-mediated signaling, the angiotensin II 
AT2 receptor is inhibitory and capable of 
disrupting receptor-stimulated Gαq/11 
activation under specific conditions (11). 
Moreover, several studies link the AT2 
receptor to diverse neuronal functions related 
to behavior (12), apoptosis (13) and memory 
(14). Focusing on the inhibitory AT2 receptor 
as potential candidate accounting for defective 
Gαq/11 activation in AD, we identified cross-
linked oligomeric AT2 receptors that form by a 
two-step cross-linking process triggered by 
aggregated Aβ. 
 
EXPERIMENTAL PROCEDURES 
 
Functional assays- Basal and stimulated 
binding of [35S]GTPγS (specific activity 1250 
Ci/mmol; final concentration 0.5 nM) to Gαq/11 
was determined in the presence of 0.1 µM 
GDP in a volume of 200 µl in triplicates with 
membranes (25 µg protein/point) prepared 
from human prefrontal cortex specimens and 
mouse hippocampal tissue as described (15) 
followed by immuno-affinity enrichment of 
Gαq/11. The method measures specifically the 
activation of Gαq/11 because the applied 
antibodies cross-react specifically with Gαq/11 
as determined in immunoblot. The assay of 
[3H|phosphatidylinositol hydrolysis was 
carried out in triplicates with membranes (100 
µg protein/point) of human prefrontal cortex 
specimens as detailed previously (6). 
Transglutaminase activity was determined by a 
[3H]putrescine incorporation assay (15). 
Immuno-affinity enrichment of Gαq/11 
followed by immunoblot detection of co-
enriched AT2 was performed by a method that 
was described (16). 
Activities of α-secretase and β-
secretase present in hippocampal tissue of 13-
month-old non-stressed and stressed APPSw 
mice were determined using commercially 
available secretase kits (R&D Systems). 
Soluble and aggregated Aβ peptide levels 
(Aβ1-40, Aβ1-42) were determined in supernatant 
(SDS-soluble) and the formic acid extract of 
the pellet (SDS-insoluble) of hippocampal 
tissue preparations from 13-month-old non-
stressed and stressed APPSw mice using a 
sandwich ELISA (Invitrogen). 
Antibodies for immunoblotting and 
immunohistochemistry- The following 
antibodies were used for immunoblotting, 
affinity purification and immuno-
histochemistry (11,15,16): affinity-purified 
rabbit/rat polyclonal anti-AT2 antibodies  
(raised against an antigen encompassing amino 
acids 320-349 of the human AT2 receptor); 
affinity-purified rabbit polyclonal anti-AT2 
antibodies  (raised against an antigen 
encompassing amino acids 16-35 of the human 
or mouse AT2 receptor); affinity-purified 
rabbit/rat polyclonal anti-M1 antibodies  
(raised against an antigen encompassing amino 
acids 231-350 of the human M1 receptor); 
affinity-purified rabbit polyclonal anti-
transglutaminase antibodies  (raised against an 
antigen encompassing amino acids 1-20 of 
mouse transglutaminase-2); affinity-purified 
rabbit polyclonal anti-Gαq/11 antibodies  (raised 
against the C-terminus of Gαq/11). 
Immunoblotting and immunohistochemistry 
were routinely used to determine and confirm 
cross-reactivity of the antibodies with the 
respective proteins (11,15,16).  
Protein detection in immunoblot- Insoluble, 
formic acid (70 %) extractable Aβ in the 
prefrontal cortex specimens indicative of Aβ 
plaque load was assessed by immunoblot with 
Aβ-specific rat polyclonal antibodies after 
serial extraction in the presence of protease 
inhibitors by high salt (150 mM Tris pH 7.6, 
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750 mM NaCl, 2mM EDTA) and detergents (1 
% Triton X-100 in high salt buffer followed by 
RIPA buffer, and 2 % SDS in 150 mM Tris, 
pH 7.6). 
 Membranes were prepared by sucrose 
density gradient centrifugation at 4 °C 
followed by partial enrichment (16). Briefly, 
membranes (500 µg protein/1.5 ml containing 
~ 300-400 fmol/mg AT2) were solubilized by 
20 mM CHAPS in 50 mM Tris, pH 7.4 
supplemented with 1 mM EDTA and protease 
inhibitor cocktail (Sigma). Particulate material 
was removed by centrifugation at 20 000 x g 
for 15 min at 4 °C. The solublilized proteins 
were precipitated and delipidated by 
acetone/methanol (12:2; final concentration 83 
%) for 90 min at 4 °C. The precipitate was 
collected by centrifugation, followed by three 
washing steps with 0.2 ml cold acetone. The 
pellet was dissolved in SDS-sample buffer 
containing 2% SDS, 5% β-mercaptoethanol 
and 6 M urea for 90 min at room temperature 
and stored for further use at -70°C. For 
immunoblotting analysis, protein samples were 
separated by SDS-PAGE under reducing 
conditions and supplemented with urea 
followed by transfer to PVDF membranes as 
described (15). Affinity-purified antibodies or 
F(ab)2 fragments of the respective antibodies 
pre-absorbed to human and mouse proteins, 
respectively, were used for detection of AT2, 
AT1 receptors, and Gαq/11. Applied antibodies 
were characterized in previous studies (11,15-
17). Bound antibody was visualized by pre-
absorbed F(ab)2 fragments of enzyme-coupled 
secondary antibodies or by enzyme-coupled 
Protein A followed by enhanced 
chemiluminescence detection (ECL plus). 
Receptor quantification- Number of AT2 
receptors was determined with membranes (50 
µg protein/point) suspended in PBS containing 
1 % bovine serum albumin and 1 mM EDTA 
(including protease inhibitor cocktail) by 
incubation for 4 h at 4 °C with 50 nM of [125I]-
labeled F(ab)2 fragments of affinity-purified 
AT2-specific antibodies (~1 µCi) in a total 
volume of 100 µl in the presence or absence of 
a 100-fold excess of the unlabeled antibodies 
to determine nonspecific binding. Receptor-
bound antibodies were separated from free 
antibodies by rapid filtration over glass fiber 
filters (GF/B, Whatman) followed by washing 
with ice-cold incubation buffer. Bound 
radioactivity was measured in a γ-counter. The 
binding assay was standardized with affinity-
purified recombinant AT2 receptors expressed 
in Spodoptera frugiperda (Sf9) cells infected 
with a recombinant baculovirus encoding AT2.  
Patients- Prefrontal cortex specimens were 
obtained at autopsy from 10 demented 
individuals with clinical diagnosis of 
(probable) AD according to NINCDS-ADRDA 
criteria (male/female 4/6, 73 ± 2, range 63 to 
81 years, postmortem interval 3-10 h), and 
from 10 non-demented patients (male/female 
5/5, 71±2, range 60 to 78 years, postmortem 
interval 4-10 h) used as a control group. 
Informed consent was obtained from all 
patients and control individuals (or subjects` 
relatives), and the study was approved by the 
Ethical Committee, Faculty of Medicine, Ain 
Shams University. 
Transgenic animals- Transgenic mice 
(Tg2576; Taconic) used in this study express 
human APP695 with the double mutation 
(K670N, M671L; APPSw), which was 
identified in a Swedish family with early onset 
Alzheimer`s disease (18). Non-transgenic mice 
served as a control group for immunoblotting 
studies. 
Lentiviral vector production- Vector plasmids 
were constructed for the production of third-
generation lentiviruses expressing HA-
transglutaminase-2  under control of the CMV 
promoter (Invitrogen). For RNA interference 
lentiviral constructs with Pol II driven 
expression of miRNAs targeting AT2 
(nucleotides 296-316) or β-galactosidase 
(nucleotides 1298-1318) were used. The 
generation of viral particles pseudotyped with 
the vesicular stomatitis virus G glycoprotein 
was performed with a four-plasmid system by 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung on M
arch 19, 2009 
w
w
w
.jbc.org
D
ow
nloaded from
 
 4 
transient transfection of 293T cells. Forty-eight 
hours later, the supernatants were collected. 
Titers of the lentiviral stocks were determined 
by transduction efficiency of HT1080 cells. 
High-titer stocks were obtained by 
ultracentrifugation. For stereotactic injection in 
mice, high titer lentiviral stocks were used (> 
1x107 transduction units/µl).  
Immunotherapy with Aβ1-40 peptide 
immunization- Immunotherapy of APPSw mice 
with Aβ1-40 peptide immunization was 
performed essentially as described (19) starting 
at 12 months of age. Prior to immunization, 
Aβ1-40 (2 mg/ml in PBS) was incubated for 24 
h at 37° C. Immunization was performed with 
Aβ1-40 (100 µg/injection) or PBS (control) 
mixed 1:1 with complete Freund`s adjuvant. 
Booster injections in incomplete Freund`s 
adjuvant followed 2 weeks after the first 
injection and monthly thereafter up to 18 
months. Blood samples were collected prior to 
immunization and three weeks after the initial 
immunization. Titers of anti-Aβ antibodies 
were determined by ELISA with serum 
samples from Aβ- and control- immunized 
APPSw mice. Aβ-immunized mice, which did 
not exhibit high titers of anti-Aβ antibodies, 
were not included in the study.  
At 18 months of age, APPSw transgenic 
mice were anesthetized and perfused 
intracardially with 0.1 M sodium phosphate 
buffer, pH 7.2 followed by 4 % (w/v) 
paraformaldehyde in the same buffer. Brains 
were removed, fixed >48 h in 10 % neutral 
buffered formalin, and paraffin embedded by 
standard methods. Immunoblotting and 
functional studies were performed with 
hippocampal membrane tissue isolated from 
non-fixed brain samples. 
Immunohistochemistry, radio-immunohisto-
chemistry and immunofluorescence- For 
immunohistochemistry, paraffin-embedded 
sections (8 µm, taken at 50 µm intervals for 
analyses, 10-15 sections per set) were 
deparaffinized followed by antigen retrieval 
(15). Immunohistochemical staining of 
transglutaminase-2, AT2 receptor, and M1 
receptor were performed with F(ab)2 fragments 
of pre-absorbed affinity-purified polyclonal 
antibodies (11,15). Sections were stained for 
Aβ plaques with monoclonal antibodies cross-
reacting with residues 1-12 of the Aβ peptide 
(Clone BAM-10, Sigma). Phosphorylated tau 
was visualized with AT8 antibodies (Pierce). 
Immunohistochemistry with antibodies to 
microtubule-associated protein 2 (MAP2) was 
used as a marker of neuronal cell bodies and 
dendrites (anti-MAP2 antibodies, Sigma). 
DNA strand breaks were determined in situ 
applying TUNEL technology (Roche). All 
sections were imaged with a Leica DMI6000 
microscope equipped with a DFC420 camera. 
Plaque burden was analyzed at 18 months of 
age by computerized quantitative image 
analysis of immunolabeled hippocampal areas. 
Assessment of the site and area of 
lentivirus infection was performed with 
paraffin sections obtained from brains of 17-
month-old APPSw mice five weeks after 
injection into the CA3 area of 2 µl of a 
lentivirus preparation (~1x107 transduction 
units/µl) encoding HA-transglutaminase-2. 
Lentivirus-driven expression of HA-
transglutaminase-2 was visualized by radio-
immuno-histochemistry applying anti-HA-
antibodies (Santa Cruz) followed by [125I-
labeled] secondary antibodies (specific activity 
~3000 Ci/mmol) and autoradiography. 
Immunofluorescence staining of 
phosphorylated tau, AT2 and M1 receptors was 
performed with cryosections (8 µm) of post-
fixed and frozen brains obtained from 13- or 
15- month-old APPSw mice subjected to stress 
for four weeks (short-term) or 12 weeks (long-
term), respectively. For co-localization of AT2 
and M1, affinity-purified rat anti-AT2 
antibodies and rabbit anti-M1 antibodies were 
applied (dilution 1:4000), followed by 
secondary antibodies labeled with Alexa Fluor 
488 and Alexa Fluor 546 (Molecular Probes; 
dilution 1:5000), and counterstaining with 
DAPI. Sections were imaged with a Leica 
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 5 
DMI6000 microscope equipped with a 
DFC350FX camera. 
Cerebral injection of lentiviruses and Aβ 
peptide- Expression of transglutaminase-2 in 
the hippocampus of 16 months-old APPSw 
transgenic mice was induced by stereotactic 
injection of 2 µl of a transglutaminase-
encoding lentivirus under control of the CMV-
promoter into the CA3 area of the 
hippocampus (anteroposterior -1.58 to -2.3 
mm; lateral 1.8 to 2.8; dorsoventral -2) as 
described (20). Briefly, anesthetized mice were 
placed on a Kopf stereotactic apparatus, 
coordinates were determined according to the 
Franklin and Paxinos atlas, the skin was 
delicately bored with a 0.5 ml insulin syringe 
equipped with a 30-gauge needle, and 
lentiviruses (~1x107 transduction units/µl) 
were delivered using a 10 µl Hamilton syringe 
with a 33-gauge blunt tip needle at a rate of 
0.25 µl/min. The control group of 16 month-
old APPSw transgenic mice received injection 
of a control lentivirus encoding β-
galactosidase. A total of 12 APPSw transgenic 
mice per group were injected unilaterally. 
Twenty days after the lentivirus injection, mice 
were anesthetized, brains were removed after 
intracardial perfusion, injected hemispheres (or 
brains) of mice were fixed and paraffin 
embedded. Immunblotting and Gαq/11 activity 
measurement were performed with non-fixed 
hippocampal tissue isolated from the injected 
brain hemispheres.  
 For down-regulation of AT2 
expression, a lentivirus that delivers a 
microRNA (miRNA) targeting the coding 
region of AT2 (nucleotides 296-316) by RNA 
interference (RNAi) was injected into the CA1 
area of the hippocampus of 12 month-old 
APPSw mice as detailed above. The control 
group received injection of a control lentivirus 
targeting β-galactosidase (nucleotides 1298-
1318). After 1 week of recovery, mice were 
subjected to the stress paradigm for 4 weeks. 
Five weeks after the lentiviral injection, 
behavioral analysis, biochemical analysis and 
immuno-histochemistry were performed as 
described. 
Protein expression levels of lentivirus-
driven expression were routinely monitored in 
immunoblot, e.g. with anti-transglutaminase 
antibodies (~1.8- to 2.3- fold hippocampal 
over-expression compared to mice injected 
with a control lentivirus encoding β-
galactosidase).  
 To assess the effect of Aβ on AT2 
oligomerization in vivo, indicated amounts of 
the Aβ1-40 peptide in 2 µl were microinjected 
under anaesthesia into the CA1 area of the 
hippocampus of 13-month-old non-transgenic 
mice as described (21,22). Vehicle was used as 
control. Seven days after the injection, 
biochemical analysis of AT2 receptors was 
performed by immunoblot. 
Induction of stress- To analyze the effect of 
stress, 12 month-old APPSw transgenic mice 
were distributed into two subgroups, one 
subgroup was housed in normal conditions 
(non-stressed) and the other subgroup was 
subjected to stress (stressed) as described (23). 
The following stimuli were administered each 
week in a random order, for four weeks: 3h of 
45° cage tilt, two times a week; soaked cage 
for 12 h, once a week; water deprivation for 14 
h, once a week; lights on for 9 h during the 
dark phase, once a week; noise in the room for 
3 h, three times a week; flashing light for 30 
min, three times a week. Stressed mice with a 
significant decrease in sucrose preference (≤ 
50% of sucrose consumption compared to non-
stressed controls) were included in the study. 
Stressed mice also exhibited a significant 
increase in plasma corticosterone levels 
(11.4±0.6 µg/dl of stressed APPSw mice and 
5.2±0.5 µg/dl of non-stressed APPSw mice; 
n=12 mice/group). After 28 days of stress, 4h 
before beginning of the dark phase, brains 
from stressed and non-stressed APPSw mice 
were removed and processed for 
immunoblotting, functional studies, and 
immunohistochemistry as described above. 
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Twelve animals of each subgroup were used 
for behavioral studies.  
Behavioral studies- We used the standard 
water maze task (hidden platform) to test for 
spatial memory (24). Testing involved four 
trials per day over 10 days starting after the 
stress period. On the day following the 10 days 
of acquisition testing, memory retention was 
determined in a single 60-s probe trial for 
which the submerged platform was removed. 
All behavioral studies were performed 
essentially as described (25). 
Animal experiments were reviewed 
and approved by the committees on animal 
research at the Universities of Hamburg and 
Cairo, and were conducted in accordance with 
the NIH guidelines.  
Statistics- Unless otherwise stated, data are 
expressed as mean ± s.e.m. To determine 
significance between two groups, we made 
comparisons using the unpaired two-tailed 
Student`s t-test. P values < 0.05 were 
considered significant. 
 
RESULTS 
 
 Impaired Gαq/11-stimulated signaling 
on prefrontal cortex specimens of AD patients. 
Prefrontal cortex specimens of AD patients 
with significant levels of "insoluble" amyloid β 
(Aβ) characteristic of Aβ plaque load (Fig. 1A) 
were applied to analyze the G-protein 
signaling defect. Specimens of AD patients 
were characterized by impaired Gq/11-
stimulated signaling as revealed by 
significantly reduced phosphoinositide 
hydrolysis under basal conditions or upon 
stimulation with the muscarinic receptor 
agonist carbachol, and the G-protein activators 
GTPγS or AlF4- (Fig. 1B). By contrast, direct 
stimulation of phospholipases C by calcium 
was not different between AD cases and non-
demented controls (Fig. 1B). Post mortem time 
(≤10 h) did not significantly affect the 
phosphoinositide signal (data not shown). 
These findings with prefrontal cortex 
specimens from AD patients confirm previous 
data of defective Gαq/11-stimulated 
phosphoinositide signaling in AD (4-8). 
 Oligomeric AT2 receptors in AD 
patients. We hypothesized that the neuronal 
angiotensin II AT2 receptor could be involved 
in the Gαq/11 signaling defect of AD patients 
because the AT2 receptor is one of the few 
inhibitory receptors capable of disrupting 
receptor-stimulated Gαq/11 activation under 
specific conditions (11). Moreover, several 
studies link the AT2 receptor to cerebral 
functions related to behavior, neuronal 
apoptosis and memory (12-14). To determine 
the AT2 receptor protein in immunoblot, we 
applied AT2-specific antibodies (11). The AT2-
specific antibodies cross-reacted with the AT2 
receptor of ~65±5 K of receptor-transfected 
human embryonic kidney (HEK) cells, 
whereas AT2 was absent in the mock control 
(Fig. 1C, left panel). AT2 receptors expressed 
in HEK cells appeared predominantly as a 
monomer of ~65 K, even when receptor 
expression levels were >5 pmol/mg protein 
(Fig. 1C, left panel). In contrast to the 
monomeric AT2 receptor of HEK cells, the 
AT2 protein on AD specimens showed 
significant levels of a high molecular mass 
AT2 receptor of ~250 K under urea-
supplemented reducing conditions of SDS-
PAGE (Fig. 1C, left versus right panel). In 
addition to the high molecular mass AT2 
receptor, the monomeric AT2 receptor of 
~65±5 K and minute amounts of an SDS-stable 
dimeric form of ~130 K were detected (Fig. 
1C, right panel). The high molecular mass AT2 
receptor was completely absent on specimens 
of non-demented control individuals (Fig. 1C, 
right panel). Pre-absorption of the antibodies 
with the immunizing antigen abolished the 
specific interaction confirming antibody 
specificity (Fig. 1C, right panel). As a control - 
and in agreement with previous results (7) - 
protein levels of membrane-bound Gαq/11 were 
similar between the two groups (Fig. 1C, lower 
panel). Post mortem time (≤10h) and gender 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung on M
arch 19, 2009 
w
w
w
.jbc.org
D
ow
nloaded from
 
 7 
did not significantly affect AT2 and Gαq/11 
levels (data not shown). Together these 
findings demonstrate a high molecular mass 
oligomeric AT2 receptor protein in AD patients 
that is absent in non-demented individuals.  
In contrast to the AT2 receptor, the 
AT1 receptor on prefrontal cortex specimens of 
AD patients appeared as a pure monomer when 
detected in immunoblot with AT1-specific 
antibodies (Fig. 1D). Thus, AT2 receptors are 
specifically altered in AD while the closely 
related AT1 receptor is not affected. 
 Sequestration of Gαq/11 by AT2 
receptor oligomers in AD patients. The 
oligomeric AT2 receptor on prefrontal cortex 
specimens of AD patients bound specifically to 
Gαq/11 in the absence of agonist as determined 
by co-enrichment, while AT2 receptors of 
control individuals did not interact 
significantly with Gαq/11 (Fig. 1E). The 
interaction of oligomeric AT2 with Gαq/11 in 
AD was paralleled by Gαq/11 dysfunction as 
detected by significantly reduced Gαq/11 
activation either under basal conditions or 
upon stimulation with carbachol (Fig. 1F). 
These findings suggest that the AT2 oligomer 
of AD patients could act as a dominant-
negative receptor that inhibits G-proteins by 
sequestration (26). 
 Aβ triggers AT2 oligomerization in 
vivo. Since the previous experiments suggested 
an involvement of AT2 oligomers in the G-
protein dysfunction of AD patients we asked 
for a causal relationship between AT2 
oligomers and aggregated Aβ as a prominent 
feature of AD. Cerebral microinjection of 
(aggregated) Aβ sufficient to induce symptoms 
of cognitive impairment and neuronal 
degeneration (21,22), into the hippocampus of 
non-transgenic mice triggered the sequential 
dimerization/oligomerization of AT2 receptors 
in a dose-dependent manner (Fig. 2A). This 
experiment provides strong evidence for a 
direct involvement of Aβ in inducing AT2 
oligomers in vivo. 
 Formation of AT2 oligomers in an 
animal model of AD. To further analyze the 
formation of AT2 oligomers in vivo, we chose 
APPSw transgenic mice as an animal model of 
AD (18). These mice develop Aβ plaques with 
increasing age (18), however major symptoms 
of clinical AD, i.e. neurodegeneration and 
memory impairment are not profound in 
APPSw transgenic mice (25, 27). To enhance 
the Aβ-dependent neurodegenerative process 
as a typical feature of AD, stress was used as 
an environmental factor that is known to 
promote the progression of AD in patients and 
mice (28-30). Stress enhanced the formation of 
aggregated SDS-insoluble Aβ and SDS-
soluble Aβ in APPSw transgenic mice (Fig. 
2B,C). Stress also marginally promoted the 
amyloidogenic processing of Aβ by decreasing 
the activity of α-secretase, and increasing the 
activity of β-secretase (Fig. 2D,E). The stress-
induced increase in aggregated Aβ species was 
accompanied by the induction of AT2 
oligomers (Fig. 2F). In contrast, the AT2 
receptors of non-stressed APPSw transgenic 
mice with significantly lower levels of 
aggregated Aβ appeared as a monomer and 
dimer (Fig. 2F). These findings are 
complementary to the sequential induction of 
AT2 dimers/oligomers by microinjected Aβ in 
non-transgenic mice (cf. Fig. 2A). 
 Progressive neurodegeneration in 
stressed APPSw mice. In view of the increased 
Aβ generation and the induction of AT2 
oligomers by stress, we asked whether the 
characteristic AD-related neurodegenerative 
process was also enhanced in APPSw mice by 
stress. Four weeks of stress led to increased 
symptoms of dendritic degeneration in the 
hippocampal CA1 area of 13 month-old APPSw 
transgenic mice as revealed by immuno-
histochemistry with MAP2-specific antibodies 
(Fig. 3A). Stress also induced DNA-strand 
breaks as determined by TUNEL assay (Fig. 
3B). Tau phosphorylation as a marker of 
degenerating neurons (31) was also 
significantly higher in the hippocampal CA1-
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 8 
CA3 area of stressed APPSw mice as 
determined by immunohistochemistry with 
AT8 antibodies (Fig. 3C). Quantification by 
[125I]-labeled AT8 antibodies confirmed the 
increase in phosphorylated tau levels in the 
CA1 area of stressed APPSw mice (Table I).  
Concomitantly to neurodegenerative 
symptoms, APPSw transgenic mice with stress-
enhanced Aβ aggregation showed significant 
impairment of a typical CA1-mediated 
learning task as measured by the water maze 
acquisition (Fig. 3D) and memory retention 
test (Fig. 3E).  
 Analogously to AD patients (32), tau 
phosphorylation preceded neuronal loss in the 
CA1 area of APPSw mice (Fig. 3F). 
Quantification with neuronal-specific NeuN 
antibodies showed a decrease of neuronal cell 
bodies by ~22 % in the CA1 area of stressed 
APPSw mice compared to nonstressed mice 
(Table I). Intraneuronal accumulation of 
phosphorylated tau was evident in remaining 
CA1 neurons (Fig. 3G). In agreement with a 
potential role of AT2 oligomers in tau-positive 
degenerating neurons, immunofluorescence 
revealed prominent AT2 receptor membrane 
localization in CA-1 neurons that were AT8-
positive (Fig. 3H). Thus, stress induced AT2 
oligomerization, and triggered a pathological 
sequence of neurodegenerative events in 
APPSw mice that resembled the AD pathology 
of patients. 
 Stress induces G-protein sequestration 
by AT2 receptor oligomers and Gαq/11 
dysfunction in APPSw mice. Similarly to AD 
patients (cf. Fig. 1E), AT2 oligomers of 
stressed APPSw mice sequestered Gαq/11 while 
AT2 receptor monomers and dimers did not 
interact with Gαq/11 (Fig. 4A, B). 
We next analyzed whether the 
induction of AT2 oligomers led to Gαq/11 
impairment. To assess Gαq/11 dysfunction, we 
chose the G(α)q/11-coupled muscarinic M1 
receptor, because impaired G-protein coupling 
of M1 correlates with disease severity in AD 
(8). The muscarinic agonist carbachol 
stimulated the activation of Gαq/11 proteins in 
the hippocampus of APPSw mice (Fig. 4C, 
columns 1,2), and this signal was 
predominantly mediated by the M1 receptor as 
evidenced by inhibition with the M1-selective 
antagonist MT-7 (Fig. 4C, columns 3,4). The 
activation of Gαq/11 under basal conditions and 
after M1 stimulation was significantly reduced 
in stressed APPSw mice with Gαq/11-
sequestering AT2 oligomers, compared to non-
stressed APPSw mice (Fig. 4D). Thus, APPSw 
mice with stress-enhanced neurodegeneration 
displayed G-protein-sequestering AT2 
oligomers and Gαq/11 dysfunction. 
 To assess the direct relationship 
between Gαq/11-sequestering AT2 oligomers 
and impaired M1-stimulated Gαq/11 activation, 
we determined the localization of M1 and AT2. 
Immunohistochemistry revealed hippocampal 
localization of M1 receptors in the CA1-CA4 
area and the dentate gyrus of APPSw mice with 
stress-enhanced neurodegeneration (Fig. 4E, 
left panel). In contrast, the AT2 receptor was 
only prominent in those regions of the 
hippocampus that also displayed tau 
phosphorylation, i.e. CA1-CA3 (Fig. 4E, right 
panel and cf. Fig. 3C). Pre-absorption of the 
antibodies confirmed antibody specificity (Fig. 
4E, lower panels).  
Hippocampal co-localization of AT2 and 
Gαq/11-coupled M1 receptors. We next 
investigated the co-localization of AT2 and M1. 
Immuno-fluorescence revealed extensive co-
localization of AT2 and M1 receptors in CA1 
neurons of the hippocampus of stressed APPSw 
mice (Fig. 5A). Notably, all neurons that 
expressed AT2 were also positive for M1 (Fig. 
5A). As a control, pre-absorption of the 
antibodies with the immunizing antigen 
abolished the specific staining (Fig. 5B). The 
expression levels of hippocampal AT2 and M1 
receptors were comparable (63±4 fmol/mg 
protein and 91±7 fmol/mg protein, 
respectively; n=4 mice/group; data not shown), 
and stress did not alter the total number of M1 
receptors (91±7 and 89±5 fmol/mg protein of 
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 9 
stressed and non-stressed APPSw mice, 
respectively; n=4 mice/group; data not shown). 
Thus, AT2 and M1 receptors are co-localized in 
the hippocampal CA1 area of APPSw mice with 
impaired M1-stimulated Gαq/11 activation. 
 Down-regulation of AT2 oligomers by 
RNA interference delayed the development of 
Gαq/11 dysfunction, and tau phosphorylation. 
To explore whether Gαq/11-sequestering AT2 
receptors were directly involved in the 
impairment of Gαq/11, we specifically down-
regulated the expression of hippocampal AT2 
in stressed APPSw mice by RNA interference. 
Injection of a lentivirus into the CA1 area 
targeting the AT2 coding sequence by a micro-
RNA led to a substantial down-regulation of 
AT2 expression as assessed by 
immunohistochemistry whereas the expression 
of M1 was not affected (Fig. 6A, B). 
Concomitantly, the amount of AT2 receptor 
oligomers was substantially reduced (Fig. 6C). 
Upon down-regulation of AT2, the 
development of Gαq/11 dysfunction was 
prevented (Fig. 6D). Complementary to 
previous findings (33), intact M1 receptor 
signaling upon down-regulation of AT2 was 
accompanied by significantly lower levels of 
phosphorylated tau as a marker of 
degenerating neurons compared to control 
mice with impaired M1 receptor signaling (Fig. 
6E).  
 Down-regulation of AT2 receptor(s) 
(oligomers) also prevented the stress-induced 
decrease in α-secretase activity (Fig. 6F), and 
delayed the generation of SDS-soluble and 
insoluble Aβ (Fig. 6G,H). The latter effects of 
AT2 oligomers seem to be directly linked to 
Gαq/11 dysfunction because intact Gαq/11-
stimulated signaling is known to mediate 
activation of α-secretase (34,35). Together 
these findings provide strong evidence for a 
causal role of AT2 (receptors) oligomers in the 
AD-related Gαq/11 dysfunction in vivo. 
 Aβ induces oxidative and 
transglutaminase-dependent cross-linking of 
AT2 receptors in vivo. In view of the 
pathophysiological importance of AT2 
oligomers, we determined the mechanism of 
AT2 oligomerization. A two-step process 
seemed to underlie the formation of AT2 
oligomers because cerebral microinjection of 
Aβ induced the sequential dimerization-
oligomerization of AT2 receptors in a dose-
dependent manner (cf. Fig. 2A). Accordingly, 
non-transgenic mice devoid of aggregated Aβ 
showed predominantly monomeric AT2 
receptors while APPSw mice with moderate 
levels of (aggregated) Aβ displayed only 
monomers and cross-linked AT2 receptor 
dimers (Fig. 7A, lanes 1-4 versus 5-8 and cf. 
Fig. 2A, F). The initial cross-linking of AT2 
receptors leading to dimers was due to reactive 
oxygen species (ROS) generated as a 
consequence of aggregated Aβ (36) because 
reduction of Aβ plaques or ROS by 
immunization with an Aβ peptide or by 
antioxidant treatment with diferuloylmethane, 
respectively, led to significantly decreased 
levels of non-dissociable (cross-linked) AT2 
receptor dimers (Fig. 7A, lanes 9-12 and 13-
14; Fig. 7B). 
 We thought that the Aβ-induced 
oxidative dimerization could assemble AT2 
receptors for cross-linking by a 
transglutaminase because transglutaminases 
are capable to cross-link pre-assembled G-
protein-coupled receptors (15), and high 
transglutaminase activity is a characteristic 
feature of clinical AD with neurodegeneration 
(37,38). In agreement with this concept, the 
formation of AT2 oligomers was paralleled by 
the activation/induction of transglutaminase in 
APPSw mice upon stress-enhanced Aβ 
aggregation (Fig. 7C, left panel), and in non-
transgenic mice upon cerebral microinjection 
of more than 10 pg of (aggregated) Aβ (Fig. 
7C, right panel). Vice versa, expression of 
transglutaminase in non-stressed APPSw 
transgenic mice (lacking AT2 oligomers and 
elevated transglutaminase activity) by 
stereotactic injection of a lentivirus encoding 
HA-transglutaminase-2 into the CA3 area of 
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the hippocampus (Fig. 7D, E) was not only 
followed by DNA strand breaks as a marker of 
neuronal degeneration, but also induced 
Gαq/11-sequestering AT2 oligomers and Gαq/11 
dysfunction (Fig. 7F, G, H). Thus, 
transglutaminase accounts for the formation of 
Gαq/11-sequestering AT2 oligomers in vivo in 
APPSw mice. 
Altogether, the experiments are 
compatible with a two-step process leading to 
AT2 oligomers in vivo. In a first step, AT2 
receptors are oxidized by ROS. In a second 
step, the assembled AT2 receptors (dimers) are 
targeted by activated transglutaminase 
resulting in non-dissociable tetramers 
(oligomers). Both steps are related to the 
pathogenesis of AD by the sequential 
induction of ROS and transglutaminase 
activity with increasing doses of (aggregated) 
Aβ. 
 
DISCUSSION 
 
The current study identified and characterized 
AT2 receptor oligomers in brain of AD patients 
and mice. AT2 receptor oligomers assemble in 
brain by a two-step process of oxidative and 
transglutaminase-dependent cross-linking that 
is triggered consecutively by (aggregated) Aβ 
in a dose-dependent manner. An initial 
oxidative cross-linking step accounts for the 
formation of AT2 receptor dimers from 
monomers. The oxidation of AT2 is linked to 
the pathogenesis of AD because oxidation is 
due to high levels of ROS generated as a 
consequence of (aggregated) Aβ, i.e. reduction 
of Aβ plaque burden and antioxidant treatment 
of APPSw transgenic mice reduced the amount 
of oxidized AT2 receptors. By assembling AT2 
receptors, oxidative cross-linking generates the 
target for the second transglutaminase-
mediated cross-linking step leading finally to 
AT2 tetramers/oligomers. Relying on activated 
transglutaminase, the second cross-linking step 
is also linked to aggregated Aβ and the 
pathogenesis of AD, because transglutaminase 
activity is elevated in brain of AD patients 
(37,38), and cerebral microinjection of 
(aggregated) Aβ or stress-enhanced generation 
of (aggregated) Aβ in APPSw transgenic mice 
was accompanied by the activation/induction 
of transglutaminase.  
Aβ-induced AT2 oligomers seem to 
contribute to the well-known Gαq/11 
dysfunction in AD: (i) impaired activation of 
Gαq/11 in prefrontal cortex specimens of AD 
patients and hippocampal tissue of mice with 
AD-like pathology correlated with the 
appearance of AT2 oligomers, (ii) the 
formation of Gαq/11-sequestering AT2 
oligomers was causally linked to the 
pathogenesis of AD because (aggregated) Aβ-
induced ROS and transglutaminase were 
required for the formation of AT2 oligomers, 
and (iii) stereotactic inhibition of cross-linked 
AT2 oligomers by RNA interference (this 
manuscript) or a mutated AT2 receptor (second 
manuscript) prevented the development of 
Gαq/11 dysfunction. By sequestering Gαq/11 
proteins, AT2 oligomers of AD patients and 
mice seem to act as dominant-negative 
receptors because Gαq/11-sequestering AT2 
oligomers induced the virtual arrest of a 
constitutively activated Gα11-protein in vitro 
(cf. second manuscript). 
 While the Gαq/11-protein defect per se 
is a well-established hallmark of clinicial AD 
in patients (4-8), its pathophysiological role is 
barely understood. A direct relationship 
between Gαq/11 dysfunction and the 
pathogenesis of AD leading to 
neurodegeneration and dementia is suggested 
by the important role of Gαq/11 proteins in 
neuronal survival, and memory (9,10,39,40). 
In addition, many of the cognition-enhancing 
effects of acetylcholine in mice are mediated 
by Gαq/11-coupled muscarinic receptors (39). 
The M1 receptor is a major target of Gαq/11 
dysfunction of AD patients, and impaired 
Gαq/11-coupling of M1 receptors correlates with 
disease severity (8). 
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 The current study supports a 
pathophysiological role of the Gαq/11 signaling 
defect in AD, because Gαq/11-sequestering AT2 
receptor oligomers seem to be part of the Aβ-
induced neurodegenerative process during the 
progression of AD: (i) A threshold dose of 
aggregated Aβ triggers the formation of AT2 
oligomers from dimers. (ii) The induced AT2 
oligomers mediate G-protein sequestration and 
dysfunction. (iii) The resulting impairment of 
neuroprotective Gαq/11-dependent signaling 
(10,40) may enhance the neurodegenerative 
process as revealed by a decreased tau 
phosphorylation and Aβ aggregation upon 
down-regulation of AT2 (oligomers). And 
indeed, additional experiments confirmed a 
role of Gαq/11-inhibitory AT2 receptor 
oligomers in neurodegeneration, i. e. specific 
inhibition of AT2 oligomerization by an AT2 
mutant delayed the development of 
neurodegenerative symptoms in "AD mice" 
(cf. second manuscript). Aβ-induced AT2 
oligomers may thus constitute a previously 
unrecognized signature of ongoing 
neurodegeneration in AD. 
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FOOTNOTES 
 
*The abbreviations used are: AD, Alzheimer`s Disease; Aβ, amyloid β; APPSw mice, transgenic 
mice expressing human APP695 with the double mutation (K670N, M671L), which was 
identified in a Swedish family with early onset Alzheimer`s disease. 
 
This manuscript is accompanied by a second study entitled "Dominant-negative AT2 receptor 
oligomers induce G-protein arrest and symptoms of neurodegeneration".  
 
 
FIGURE LEGENDS 
 
Fig. 1. AT2 receptor oligomers and G-protein dysfunction in AD patients. A. Immunoblot of 
"insoluble" Aβ on prefrontal cortex specimens (Cortex) of five AD patients (AD) indicative of 
plaque load whereas "insoluble" Aβ was barely detectable in samples of five non-demented 
control individuals (Controls). Positions of Aβ40,42 are marked by arrowheads. As a control, pre-
absorption of the antibodies by the immunizing antigen (+a) abolished the specific staining. B. 
Significantly reduced phosphatidylinositol hydrolysis (PI hydrolysis) on prefrontal cortex 
membranes (Cortex) of 10 AD patients (AD) compared to 10 non-demented controls (Con) under 
basal conditions and upon stimulation with carbachol (Cch, 1 mM), the G-protein activators 
GTPγS (3 µM), and AlF4- (10 µM). PI hydrolysis after direct PLC stimulation by Ca2+ (10 µM) 
was not significantly different. Data represent mean ± s.e.m., n=10 patients per group (*P < 0.03, 
**P < 0.003). C. Left panel: Immunoblot detection of AT2 receptors with affinity-purified F(ab)2 
fragments of AT2-specific antibodies pre-absorbed to human proteins (IB: anti-AT2) on 
membranes of HEK cells (HEK) over-expressing high levels (~ 5 pmol/mg) of AT2 (lane 1) 
compared to mock-transfected cells (lane 2). Right panel: Immunoblot detection of partially 
enriched AT2 receptors on prefrontal cortex membranes of five AD patients (AD) compared to 
five non-demented control individuals (Controls). Arrowheads mark oligomeric (O), dimeric (D) 
and monomeric (M) AT2. Pre-absorption of the antibodies by the immunizing antigen (+a) 
abolished the specific staining. The lower panel shows a control immunoblot detecting Gαq/11. D. 
Left panel: Immunoblot of AT1 receptors detected with affinity-purified F(ab)2 fragments of AT1-
specific antibodies (IB: anti-AT1) on membranes of HEK cells (HEK) expressing AT1 (lane 1) 
compared to mock-transfected cells (lane 2). Right panel: Immunoblot detection of partially 
enriched AT1 receptors on prefrontal cortex membranes of five AD patients (AD) compared to 
five non-demented control individuals (Controls). Pre-absorption of the antibodies by the 
immunizing antigen (+a) abolished the specific staining. E. Immunoblot of AT2 receptors co-
enriched with affinity-purified Gαq/11 (AP: anti-q/11; IB: anti-AT2) from prefrontal cortex 
membranes of 5 AD patients (AD) and 5 non-demented control individuals (Controls). The lower 
panel shows equal enrichment of Gαq/11 (AP, IB: anti-q/11). F. Decreased Gαq/11 activation on 
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prefrontal cortex membranes of 10 AD patients compared to 10 control individuals as determined 
by [35S]GTPγS binding under basal conditions and upon carbachol stimulation (Cch) followed by 
immuno-affinity enrichment of Gαq/11. Data represent mean ± s.e.m., n=10 (**P < 0.001).  
 
Fig. 2. Aβ-induced AT2 oligomers in mice. A. Partially enriched AT2 receptors on hippocampal 
membranes of non-transgenic mice 7 days after cerebral microinjection of the indicated amounts 
of Aβ1-40 (2 µl) into the hippocampus as determined by immunoblot with F(ab)2 fragments of 
affinity-purified AT2-specific antibodies (IB: anti-AT2) pre-absorbed to mouse proteins. B & C. 
Four weeks of stress (Stressed) led to increased levels of SDS-insoluble (B) and SDS-soluble (C) 
Aβ (Aβ1-40; Aβ1-42) in the hippocampus of 13-month-old APPSw mice compared to non-stressed 
APPSw mice (Non-stressed). Data represent mean ± s.e.m., n=4 (**P < 0.001; *P < 0.05). D & E. 
Stress decreased the activity of hippocampal α-secretase in APPSw mice (D) and led to increased 
activity of hippocampal β-secretase (E). Data are given as percentage of control, i. e. the α-
secretase or β-secretase activity of non-stressed mice, respectively (i. e. 100 %), and represent 
mean ± s.e.m., n=4 (*P < 0.01). F. Formation of AT2 oligomers in the hippocampus of stressed 
APPSw mice as determined in immunoblot of partially enriched AT2 receptors from hippocampal 
membranes of stressed APPSw transgenic mice compared to non-stressed APPSw transgenic mice 
applying F(ab)2 fragments of affinity-purified AT2-specific antibodies pre-absorbed to mouse 
proteins. 
 
Fig. 3. Progressive neurodegeneration in stressed APPSw mice. A. Symptoms of dendritic/neuritic 
degeneration in the CA1 area of stressed APPSw transgenic mice (4 weeks) compared to non-
stressed mice as determined by immunohistochemistry with anti-MAP2 antibodies (original 
magnification x 400). B. DNA strand breaks in the CA1 area of the hippocampus of stressed (4 
weeks) APPSw transgenic mice compared to non-stressed APPSw transgenic mice as determined 
by in situ TUNEL labeling (original magnification x 400). C. Stress (4 weeks) increased tau 
phosphorylation in the CA1 (and CA2-CA3) area of the hippocampus of APPSw mice (13 month-
old) as assessed by immunohistochemistry with AT8 antibodies (original magnification x 16). D. 
Significantly impaired learning of the Morris water-maze acquisition task of stressed (4 weeks) 
APPSw transgenic mice compared to non-stressed APPSw transgenic mice. Acquisition was 
measured by latency to find a stationary submerged platform over 10 training blocks. Data 
represent mean ± s.e.m., n = 12 mice per subgroup (*P < 0.01; **P < 0.0008). E. Reference 
memory retention of stressed (4 weeks) and non-stressed APPSw transgenic mice was determined 
during a single 60 s probe trial (without platform) following completion of 10 blocks of 
acquisition training. Time spent in each of the four quadrants is indicated for each group (± 
s.e.m., n = 12; *P < 0.01; ANOVA with Dunn`s multiple comparison test). F. Long-term stress 
for 12 weeks (stressed, long-term) triggered neuronal loss in the hippocampal CA1 area of 15 
month-old APPSw mice (right panel) compared to non-stressed mice (left panel) as determined by 
Nissl staining of paraffin sections (original magnification x 16). G. Phosphorylation of tau in 
CA1 neurons of stressed APPSw mice (long-term stress for 12 weeks) was determined by 
immunofluorescence with AT8 antibodies followed by visualization of bound antibodies with 
Alexa Fluor 546-labeled secondary antibodies (upper left panel). The upper right panel shows 
DAPI staining of the same section. Merged pictures show cytosolic localization of p-tau (original 
magnification: x 600; lower right panel: x 750). H. Immunofluorescence detection of AT2 
receptors (upper left panel) and phosphorylated tau (upper right panel) in CA1 neurons of APPSw 
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mice subjected to four weeks of stress (Stressed). Merged pictures (lower panels) reveal co-
localization of AT2 and p-tau (original magnification: x 400; lower right panel, x 600). 
 
Fig. 4. Stress induces G-protein sequestration by AT2 receptor oligomers and Gαq/11 dysfunction 
in APPSw mice. A. Oligomeric AT2 receptors interact specifically with Gαq/11 as determined by 
immuno-affinity enrichment of Gαq/11 and detection of co-enriched AT2 in immunoblot (AP: anti-
q/11; IB: anti-AT2). Co-enrichment was performed with hippocampal membranes of four APPSw 
transgenic mice with stress-enhanced neurodegeneration compared to four non-stressed mice. The 
lower panel shows equal enrichment of Gαq/11 from both groups (AP/IB: anti-q/11). B. Gαq/11 is 
not significantly co-enriched with hippocampal AT2 receptors of non-stressed APPSw mice (lane 
1) whereas AT2 of stressed APPSw mice interacts with Gαq/11 (lane 2) as determined by immuno-
affinity enrichment of AT2 and immunoblot detection of co-enriched Gαq/11 (AP: anti-AT2; IB: 
anti-q/11). The right panel shows equal enrichment of AT2 receptors from non-stressed (lane 3) 
and stressed (lane 4) APPSw mice (AP/IB: anti-AT2). C. The M1-selective antagonist MT-7 (100 
nM) inhibited the carbachol-stimulated (Cch) activation of Gαq/11 in the hippocampus of APPSw 
mice. Data represent mean ± s.e.m., n = 4 mice/group (*P < 0.02; **P < 0.0001). D. Reduced 
hippocampal activation of Gαq/11 of stressed APPSw mice compared to non-stressed APPSw mice. 
Data represent mean ± s.e.m., n = 4 mice/group (*P < 0.003). E. In stressed APPSw mice, M1 
receptors are localized in the hippocampal CA1-CA4 and dentate gyrus regions (left panel), 
whereas AT2 receptors are predominantly localized in CA1-CA3 (right panel) as determined by 
immunohistochemistry applying anti-M1 and anti-AT2 antibodies (original magnification x 18). 
Preabsorption controls of the antibodies are shown in the lower panels. 
 
Fig. 5. Hippocampal co-localization of AT2 and M1 receptors. A. Immunofluorescence applying 
rabbit anti-M1 antibodies (upper left panel) and rat anti-AT2 antibodies (upper right panel) 
revealed extensive co-localization of M1 and AT2 receptors in CA1 neurons of stressed (4 weeks) 
APPSw transgenic mice (Merge/colocalization - lower left panel). Lower right panel: hematoxylin 
staining of the section. B, Preabsorption controls confirm specificity of the applied antibodies 
(original magnification x 300). 
 
Fig. 6. Down-regulation of AT2 oligomers by RNA interference delayed the development of 
Gαq/11 dysfunction, and tau phosphorylation. A. AT2 protein expression (anti-AT2) was 
determined by immunohistochemistry in the CA1 area of stressed APPSw mice injected with a 
control lentivirus targeting β-galactosidase (left panel - Control RNAi) or with a lentivirus 
targeting AT2 by RNA interference (right panel - AT2-RNAi; original magnification x 600). B. 
M1 receptor protein expression was determined by immunohistochemistry (anti-M1) in the CA1 
area of stressed APPSw mice injected with a control lentivirus (left panel - control RNAi) or with 
a lentivirus targeting AT2 by RNA interference (right panel - AT2 RNAi; original magnification x 
600). C. Immunoblot detection of AT2 receptors with anti-AT2 antibodies (IB: anti-AT2) in the 
hippocampus of stressed APPSw mice (n=4 mice/group) injected with a control lentivirus targeting 
β-galactosidase (Control-RNAi) or with a lentivirus targeting AT2 by RNA interference (AT2-
RNAi). The control immunoblot (lower panel) shows similar protein levels of Gαq/11 of the two 
groups (IB: anti-Gαq/11). D. Basal and carbachol- (Cch-) stimulated Gαq/11 activation in the 
hippocampus of stressed APPSw mice injected with a control lentivirus (Control RNAi) or with a 
lentivirus targeting AT2 by RNA interference (AT2-RNAi).  Data represent mean ± s.e.m., n = 4 
mice/group (*P < 0.05; **P < 0.001). E. Tau phosphorylation (upper panel) was determined by 
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immunoblot (IB: AT8) in the hippocampus of stressed APPSw mice (n=4 mice/group) injected 
with a control lentivirus (Control-RNAi) or with a lentivirus targeting AT2 by RNA interference 
(AT2-RNAi). A control immunoblot (IB: anti-tau; lower panel) shows equal protein levels of 
(dephosphorylated) tau of the two groups. F. Down-regulation of AT2 expression by RNA 
interference prevented the decrease in the activity of α-secretase of stressed APPSw mice (AT2-
RNAi versus Control-RNAi). Data are given as percentage of control, i. e. the α-secretase activity 
of non-stressed mice (Non-str.) injected with a control lentivirus (i. e. 100 %) and represent mean 
± s.e.m., n=4 (*P < 0.01). G & H. Levels of SDS-soluble (G) and SDS-insoluble Aβ (H) in the 
hippocampus of stressed APPSw mice injected with a control lentivirus targeting β-galactosidase 
(Control-RNAi) or with a lentivirus targeting AT2 by RNA interference (AT2-RNAi). Data 
represent mean ± s.e.m., n=4 (*P < 0.05; **P < 0.002). 
 
Fig. 7. Aβ induces oxidative and transglutaminase-dependent cross-linking of AT2 receptors in 
vivo. A. Immunoblot of partially enriched hippocampal AT2 receptors of 18 month-old non-
transgenic mice (Non-transgenic, lanes 1-4), APPSw transgenic mice (Non-treated, lanes 5-8) and 
APPSw transgenic mice subjected to immunization with the Aβ peptide (Immunized, lanes 9-12) 
to reduce plaque burden (n=4 mice/group). The lane marked with +a controls immunoblot 
specificity. Lane 14 shows hippocampal AT2 of a representative 18 month-old APPSw mouse 
treated with the antioxidant diferuloylmethane for six months (500 ppm in diet) compared to a 
non-treated control APPSw transgenic mouse (lane 13). B. Immunization of APPSw transgenic 
mice with the Aβ peptide (Immunized) significantly decreased Aβ plaque load compared to non-
treated APPSw mice (Non-treated) as determined by immuno-histochemistry with anti-Aβ 
antibodies (Anti-Aβ). Shown are brain sections representing the median degree of pathology as 
determined with 4 mice per group (original magnification x 20). C. Left panel: Increased 
hippocampal transglutaminase activity of APPSw transgenic mice subjected to stress (Stressed) 
compared to control APPSw transgenic mice housed in standard conditions (Non-stressed). Data 
are from 8 mice in each group (**P < 0.0001). Right panel: Cerebral injection of Aβ induced 
activation/induction of hippocampal transglutaminase in non-transgenic mice. Data are from 4 
mice/group (*P < 0.001). D. Expression of HA-transglutaminase in the hippocampus of a 
representative APPSw mouse five weeks after unilateral injection into the CA3 area of a lentivirus 
encoding HA-transglutaminase was determined by radio-immunohistochemistry applying anti-
HA antibodies (anti-HA) followed by [125I]-labeled secondary antibodies and autoradiography. E. 
Expression of transglutaminase in the hippocampal CA3 area of non-stressed APPSw mice 
injected with a transglutaminase-2-encoding lentivirus (+Transglut.; left panel) or with a control 
lentivirus encoding β-galactosidase (Control; right panel) was determined by 
immunohistochemistry with transglutaminase-2-specific antibodies (Anti-Transglut.; original 
magnification x 600). F. DNA strand breaks were determined by in situ TUNEL labeling in the 
CA3 area of the hippocampus of APPSw mice injected with a transglutaminase-encoding 
lentivirus (+Transglut.; left panel) or with a control lentivirus (Control; right panel; original 
magnification x 600). G. Co-enrichment of oligomeric AT2 receptors with affinity-purified Gαq/11 
(AP: anti-q/11; IB: anti-AT2) from the hippocampus of four APPSw transgenic mice injected with 
a transglutaminase-encoding lentivirus (+Transglut.) compared to mice receiving injection of a 
control lentivirus (Control). The lower panel shows equal enrichment of Gαq/11 from both groups 
(AP/IB: anti-q/11). H. Reduced hippocampal activation of Gαq/11 in APPSw transgenic mice 
injected with a transglutaminase-2-encoding lentivirus (+Transglut.) compared to mice injected 
with a control lentivirus (Control). Data represent mean ± s.e.m., n = 4 mice/group (*P < 0.003). 
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TABLE 1 
 
Stress enhances tau phosphorylation and neuronal loss in the hippocampal CA1 area of 
APPSw mice. Tau phosphorylation in CA1 of stressed and non-stressed APPSw mice was 
determined by direct binding assay with [125I]-labeled AT8 antibodies, and neuronal cell 
bodies of CA1 were quantified by [125I]-labeled NeuN antibodies, respectively (1.0 
µCi/point; final concentration 5 x 10-8 M). Binding assays were performed in triplicates 
with crude homogenates (0.5 mg protein/ml) prepared from dissected CA1 regions of 
stressed (long-term stress for 3 months) and non-stressed 15 months-old APPSw mice. 
Bound radioactivity of [125I]-labeled NeuN antibodies to neuronal cell bodies in CA1 of 
stressed APPSw mice is expressed as percentage of control, i. e. the value obtained with 
non-stressed APPSw mice, which was set to 100 %. Data represent mean ± s.e.m., n = 5 
mice/group (*P < 0.008).  
 
 Stressed APPSw mice Non-stressed APPSw mice 
Phosphorylated tau in CA1 
(ng/mg protein) 9.4 ± 1.2* 3.2 ± 0.4 
Neuronal cell bodies in 
CA1 (%) 78.4 ± 4.2* 100 ± 4 
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